ARTICLE | Company News
Shire buys Foresight for $300M
August 4, 2015 12:53 AM UTC
Shire plc (LSE:SHP; NASDAQ:SHPG) acquired ophthalmic play Foresight Biotherapeutics Inc. (New York, N.Y.) for $300 million in cash. The deal gives Shire global rights to FST-100, an ophthalmic formulation of dexamethasone and povidone-iodine to treat infectious conjunctivitis. Shire expects to begin a Phase III study of the candidate, and spokesperson Gwen Fisher said the company has not yet determined a timeline.
Shire's ophthalmic pipeline includes lifitegrast ( SAR 1118), which is under FDA review to treat dry eye with an Oct. 25 PDUFA date (see BioCentury Extra, April 9). ...